Mounjaro 12.5 mg KwikPen Injection (Tirzepatide) – Prefilled Pen

Mounjaro 12.5 mg KwikPen Injection contains Tirzepatide, a dual-acting incretin-based injectable medication indicated for the management of Type 2 Diabetes Mellitus. Tirzepatide targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors to provide advanced glycemic control.

The 12.5 mg strength is typically prescribed as a higher maintenance or escalation dose for patients requiring enhanced blood glucose control after lower doses. It helps improve insulin secretion, suppress glucagon release, slow gastric emptying, and regulate appetite.

Uses of Mounjaro 12.5 mg Injection

• Management of Type 2 Diabetes Mellitus

• Improves glycemic control along with diet and exercise

• Helps reduce fasting and post-prandial blood glucose levels

• Advanced dose for patients needing stronger glycemic control

How Mounjaro Works (Mechanism of Action)

Tirzepatide works through dual incretin receptor activation, resulting in:

• Increased glucose-dependent insulin secretion

• Reduced glucagon production

• Delayed gastric emptying

• Decreased appetite and caloric intake

These combined effects lead to improved metabolic regulation and sustained glycemic control.

Dosage and Administration

• Route: Subcutaneous injection (abdomen, thigh, or upper arm)

• Recommended Dose: 12.5 mg once weekly (as prescribed by the physician)

• Each pen delivers 4 weekly doses

• Administer on the same day each week, with or without meals

• Follow the instructions provided in the package insert

Dose escalation or adjustment should be done only under medical supervision.

Side Effects

Common Side Effects:

• Nausea

• Vomiting

• Diarrhea

• Constipation

• Decreased appetite

• Injection site reactions

Serious (Rare) Side Effects:

• Severe gastrointestinal symptoms

• Hypoglycemia (especially when used with insulin or sulfonylureas)

• Pancreatitis

• Allergic reactions

Seek immediate medical attention if serious side effects occur.

Precautions and Warnings

• Prescription-only medicine

• Not indicated for Type 1 diabetes

• Use with caution in patients with gastrointestinal disorders

• Inform your doctor about all ongoing medications

• Not recommended during pregnancy or breastfeeding unless advised

• Do not share the prefilled pen with others

Storage Instructions

• Store refrigerated at 2°C–8°C

• Do not freeze

• Protect from light

• Follow package insert instructions for storage after first use

Key Highlights

• Contains Tirzepatide 12.5 mg

• Dual GIP & GLP-1 receptor agonist

• Once-weekly injection for better patient compliance

• Easy-to-use multi-dose KwikPen

• Manufactured by Eli Lilly, a globally trusted pharmaceutical company